New Twice-Yearly shot aims to slash bad cholesterol in High-Risk patients

NCT ID NCT04765657

Ongoing Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

Summary

This study is testing whether a new injectable drug called inclisiran can safely lower 'bad' LDL cholesterol in Asian adults who have heart disease or are at high risk for it. Participants are already taking the highest dose of statin pills they can tolerate. The goal is to see if adding inclisiran injections every few months helps control cholesterol levels better than a placebo injection over one year.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Novartis Investigative Site

Lanzhou, Gansu, 730030, China
Novartis Investigative Site

Foshan, Guangdong, 528000, China
Novartis Investigative Site

Guangzhou, Guangdong, 510080, China
Novartis Investigative Site

Shijiazhuang, Hebei, 050000, China
Novartis Investigative Site

Baotou, Inner Mongolia, 014040, China
Novartis Investigative Site

Hohhot, Inner Mongolia, 010017, China
Novartis Investigative Site

Nanjing, Jiangsu, 210008, China
Novartis Investigative Site

Nanjing, Jiangsu, 211166, China
Novartis Investigative Site

Nantong, Jiangsu, 226000, China
Novartis Investigative Site

Suzhou, Jiangsu, 215004, China
Novartis Investigative Site

Xuzhou, Jiangsu, 221003, China
Novartis Investigative Site

Changchun, Jilin, 130000, China
Novartis Investigative Site

Changchun, Jilin, 130021, China
Novartis Investigative Site

Jinan, Shandong, 250013, China
Novartis Investigative Site

Zhujing, Shanghai Municipality, 201508, China
Novartis Investigative Site

Taiyuan, Shanxi, 030002, China
Novartis Investigative Site

Xian, Shanxi, 710061, China
Novartis Investigative Site

Tianjin, Tianjin Municipality, 300121, China
Novartis Investigative Site

Hangzhou, Zhejiang, 310014, China
Novartis Investigative Site

Beijing, 100034, China
Novartis Investigative Site

Beijing, 100039, China
Novartis Investigative Site

Beijing, 100050, China
Novartis Investigative Site

Beijing, 100191, China
Novartis Investigative Site

Shanghai, 200032, China
Novartis Investigative Site

Shanghai, 200040, China
Novartis Investigative Site

Shanghai, 200080, China
Novartis Investigative Site

Shanghai, 200120, China
Novartis Investigative Site

Tianjin, 300052, China
Novartis Investigative Site

Tianjin, 300140, China
Novartis Investigative Site

Xiamen, 361004, China
Novartis Investigative Site

Singapore, 119074, Singapore
Novartis Investigative Site

Singapore, 169609, Singapore
Novartis Investigative Site

Wŏnju, Gangwon-do, 26427, South Korea
Novartis Investigative Site

Incheon, Korea, 405 760, South Korea
Novartis Investigative Site

Seoul, Korea, 02841, South Korea
Novartis Investigative Site

Seoul, Korea, 03080, South Korea
Novartis Investigative Site

Seoul, Seoul, 06351, South Korea
Novartis Investigative Site

Seoul, South Korea, 110-746, South Korea
Novartis Investigative Site

Gwangju, 61469, South Korea
Novartis Investigative Site

Seoul, 03722, South Korea
Novartis Investigative Site

Seoul, 05505, South Korea
Novartis Investigative Site

Kaohsiung City, 80756, Taiwan
Novartis Investigative Site

Taipei, 10002, Taiwan
Novartis Investigative Site

Taipei, 11217, Taiwan
Novartis Investigative Site

Taipei, 11220, Taiwan

Conditions

Explore the condition pages connected to this study.

HYPERCHOLESTEROLEMIA